Factor VIII (medication): Difference between revisions
m cat |
AlphaMoron (talk | contribs) Added the drawbacks of using this preperation |
||
| Line 1: | Line 1: | ||
{{linkless|September 2006}} |
|||
'''Aafact''' is a monoclonal purified [[factor VIII]] concentrate. It consists of a protein fraction prepared from fresh-frozen [[human plasma]]. It is used in cases of acute haemorrhage, pre-operative and post-operative treatment and prophylaxis in [[haemophilia A]] patients (congenital factor VIII deficiency) and in patients with an acquired reduction in factor VIII activity. It is available as a powder for infusion for [[intravenous]] administration. |
'''Aafact''' is a monoclonal purified [[factor VIII]] concentrate. It consists of a protein fraction prepared from fresh-frozen [[human plasma]]. It is used in cases of acute haemorrhage, pre-operative and post-operative treatment and prophylaxis in [[haemophilia A]] patients (congenital factor VIII deficiency) and in patients with an acquired reduction in factor VIII activity. It is available as a powder for infusion for [[intravenous]] administration. |
||
This transfer of a [[Blood plasma|plasma]] byproduct into the blood stream of a [[hemophiliac]] often led to the transmission of diseases such as [[HIV]] and [[hepatitis]] before purification methods were improved. In the early 1990s, pharmaceutical companies began to produce [[recombinant]] synthesized factor products, which now prevent nearly all forms of disease transmission during replacement therapy. |
|||
{{pharma-stub}} |
{{pharma-stub}} |
||
Revision as of 11:15, 3 January 2007
Aafact is a monoclonal purified factor VIII concentrate. It consists of a protein fraction prepared from fresh-frozen human plasma. It is used in cases of acute haemorrhage, pre-operative and post-operative treatment and prophylaxis in haemophilia A patients (congenital factor VIII deficiency) and in patients with an acquired reduction in factor VIII activity. It is available as a powder for infusion for intravenous administration.
This transfer of a plasma byproduct into the blood stream of a hemophiliac often led to the transmission of diseases such as HIV and hepatitis before purification methods were improved. In the early 1990s, pharmaceutical companies began to produce recombinant synthesized factor products, which now prevent nearly all forms of disease transmission during replacement therapy.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |